News
Video
Author(s):
A comprehensive discussion on VEGF-TKI-based combinations and immune checkpoint inhibitor combinations in the treatment of renal cell carcinoma, featuring key clinical trial results and treatment strategies.
Time-Limited Acalabrutinib/Obinutuzumab Produces Durable Responses in Treatment-Naive CLL
Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma
V. Craig Jordan, PhD, the ‘Father of Tamoxifen,’ Dies at 76
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
Clear Cell Histology Associated With Increased Risk of irAEs in Metastatic RCC
Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition
Dr Sands on the Evolving Role of ADCs in SCLC Management
Dr Hirsch on the Treatment of NRG1 Fusion+ NSCLC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes